DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Diagnostic Equipment Market: Global Demand Analysis & Opportunity Outlook 2023” report has been added to ResearchAndMarkets.com’s offering. Global market of ophthalmic diagnostic equipment reached USD 1294.0 Million in 2016 and is expected to reach USD 1623.5 Million by the end of 2023, expanding at a CAGR of 3.4% over the forecast period i.e. 2016-2023. Geographically, North America accounted for the largest market share of 32.7% in 2016 in the reve
Author: Business Wire
Investigation Report on Chinese Latanoprost Market, 2018-2022: Basic Concepts, Sales, Major Manufacturers, Prices & Market Prospects – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Investigation Report on Chinese Latanoprost Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering. Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, Ch…
2018 Diabetic Retinopathy Pipeline Highlights – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Diabetic Retinopathy Pipeline Highlights – 2018” report has been added to ResearchAndMarkets.com’s offering. This report provides most up-to-date information on key pipeline products in the global Diabetic retinopathy mark…
Global Ocular Implants Market 2018-2022 | 13% CAGR Projection Over the Next Four Years | Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–The global ocular implants market 2018-2022 is expected to post a CAGR of around 13% during the forecast period, according to Technavio.
Omeros Corporation Initiates Sales of OMIDRIA® in Europe
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union (EU) for use in cataract and lens replacement surgery to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. These sales satisfy the “sunset clause” provision in the EU a
BioTime to Announce Second Quarter 2018 Results on August 2, 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, August 2, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and recent corporate developments. The
Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura presented interim data from an open-label Phase 1b/2 study of light-activated AU-011 for the treatment of primary choroidal melanoma.
Uveal melanoma| A Pipeline Analysis Report 2018| Technavio
LONDON–(BUSINESS WIRE)–#InfectiousDiseases–Technavio has published a new report on the drug development pipeline for uveal melanoma, including a detailed study of the pipeline molecules.
Retinitis Pigmentosa | A Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has published a new report on the drug development pipeline for retinitis pigmentosa, including a detailed study of the pipeline molecules.
Global Macular Degeneration Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Macular Degeneration Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering. Macular Degeneration ongoing clinical trials report provides comprehensive analysis and …
Hemovent meldet „beeindruckende Ergebnisse“ aus GLP-konformer standardisierter In-vivo-Studie zur Langzeitanwendung des Systems für die extrakorporale Membranoxygenierung (ExtraCorporeal Membrane Oxygenation, ECMO) der nächsten Generation, Mobybox™
AACHEN, Deutschland–(BUSINESS WIRE)–Hemovent GmbH meldete heute den erfolgreichen Abschluss einer GLP-konformen standardisierten In-vivo-Studie zur Langzeitanwendung (7 Tage) ihrer neuartigen und tragbaren Bionique-Technologieplattform für die künstliche Lunge, die auf eine Vielzahl von Indikationen ausgerichtet ist: von der extrakorporalen Lebensunterstützung (ExtraCorporeal Life Support, ECLS) bis zur extrakorporalen CO2-Elimination (ExtraCorporeal CO2 Removal, ECCO2R). „Wir sind mit unsere
Researchers Move Closer to Completely Optical Artificial Neural Network
WASHINGTON–(BUSINESS WIRE)–#AI–Researchers have shown that it is possible to train artificial neural networks directly on an optical chip.
Hemovent Reports “Stunning Results” from Completion of GLP Standardized in vivo Trial for Long-Term Use of Its Next-Gen ExtraCorporeal Membrane Oxygenation (ECMO) System Mobybox™
AACHEN, Germany–(BUSINESS WIRE)–Hemovent reports “stunning results” from completion of GLP standardized in vivo trial
Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA®
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has received acknowledgement from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for DEXTENZA® has been received. DEXTENZA (dexamethasone insert) 0.4mg is Ocular Therapeutix’s lead product candidate for the treat
Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release second quarter 2018 financial results after the market close on Thursday, August 2, 2018. The company’s management will discuss the results during a conference call and simultaneous webc
Global Night Vision Devices Market Analysis, Trends, Share, Size, Growth, Opportunity & Forecast 2018-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Night Vision Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. The global Night Vision Devices market reached a val…
Secondo uno studio clinico, il LED SunLike di Seoul Semiconductor migliora la salute oculare e la qualità del sonno
ANSAN, Corea del Sud–(BUSINESS WIRE)–Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), leader del settore in quanto a progettazione e produzione di diodi ad emissione di luce (light emitting diode, LED) operante su scala globale, ha annunciato che uno studio ha dimostrato che la sua tecnologia“SunLike” costituisce un LED ottimizzato per lo “human centric lighting” che è in grado di migliorare la salute oculare e la qualità del sonno. Il team del Laboratorio di informatica biomedica (Biomedical I
Selon une étude clinique, la technologie SunLike de Seoul Semiconductor améliore la santé des yeux et la qualité du sommeil
ANSAN, Corée du Sud–(BUSINESS WIRE)–Seoul Semiconductor Co., Ltd. (KOSDAQ : 046890), un leader mondial sur le marché de la conception et de la fabrication de diodes électroluminescentes (light emitting diodes, LED), a annoncé qu’une recherche avait montré que sa technologie « SunLike » offrait une LED optimisée pour l’éclairage centré sur l’homme et permettait d’améliorer la santé des yeux et la qualité du sommeil. L’équipe de recherche du Laboratoire d’information biomédicale de la faculté d
SunLike-LED von Seoul Semiconductor verbessert die Augengesundheit und Schlafqualität, so eine klinische Studie
ANSAN, Südkorea–(BUSINESS WIRE)–Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), einer der weltweiten Marktführer im Design und der Herstellung von LEDs (Leuchtdioden), gab bekannt, dass eine Studie gezeigt hat, dass sein Produkt „SunLike“ eine optimierte LED für auf den Menschen ausgerichtete Beleuchtung ist, mit der Augengesundheit und Schlafqualität verbessert werden. Das Forschungsteam des Biomedical Information Laboratory am Seoul National University College of Medicine in Südkorea bericht
IngenioSpec’s Smart Eyewear for Seniors
SAN JOSE, Calif.–(BUSINESS WIRE)–IngenioSpec offers patent-protected smart eyewear technologies for seniors. As the elderly population continues to grow, technologies for aging will become crucial for ensuring seniors’ well-being. Existing devices and services attempt to address some of these needs, but can be unwieldy and conspicuous. IngenioSpec technology envisions a discreet, stylish product combining the ultimate in ease-of-use with compact, lightweight electronics in an item many senior